Lipitor Generic Bottleneck Needs To Be Cleared "Now," Senators Tells FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Without suggesting a specific action, five Democratic senators urge a "timely action" from FDA on "previous filings."
You may also be interested in...
Lipitor Generics: Ranbaxy Still In The Driver's Seat As Court Dismisses Mylan Lawsuit Against U.S. FDA
Two unresolved factual matters stand in the way of Mylan Pharmaceuticals Inc.' s bid to sue U.S. FDA over generic marketing exclusivity for Pfizer's Lipitor, a U.S. federal judge ruled May 2
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
Judge Boasberg says the court should not "prematurely intrude" on FDA resolution of two factual issues: the approvability of Mylan's atorvastatin ANDA and any generic marketing exclusivity determination involving Ranbaxy.
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
Judge Boasberg says the court should not "prematurely intrude" on FDA resolution of two factual issues: the approvability of Mylan's atorvastatin ANDA and any generic marketing exclusivity determination involving Ranbaxy.